Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential gene expression analysis of Mice liver treated with Amodiaquine and Sulfodoxine-Pyrimethamine

ABSTRACT: The study describes the differential gene expression analysis in murine liver following dosing with human therapeutic equivalent doses of Amodiaquine and Sulfodoxine-Pyrimethamine antimalarial drugs.The dosing was decided based on standard antimalarial therapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE17392 | GEO | 2011/06/21

SECONDARY ACCESSION(S): PRJNA118831

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Microarray analysis of murine kidney treated with Amodiaquine and Sulfodoxine-Pyrimethamine

2014-12-23 | GSE19157 | GEO

Microarray analysis of murine kidney treated with Amodiaquine and Sulfodoxine-Pyrimethamine

Project description:Differential gene expression in mice kidney after Amodiaquine and Sulfodoxine-Pyrimethamine anti-malaria treatments were evaluated. Dosages were decided based on standard malaria therapy in human. Mice (Mus musculus) belonging to control and Amodiaquine and Sulfodoxine-Pyrimethamine administered groups (n=4) were sacrificed. The kidneys were snap frozen in liquid nitrogen, and subsequently stored at -80M-BM-:C till further use. Kidney samples were homogenized and total RNA was extracted with TRI reagent. 25 ug of total RNA was converted into labeled cDNA using CyScribe first strand cDNA labeling kit. The Cy5 and Cy3 labeled cDNAs were resuspended in Cyscribe Hyb buffer containing 10ug/ml sheared Salmon sperm DNA and 10ug/ml Yeast tRNA. The labeled samples were hybridized to the arrays and incubated for 16-18hrs at 42M-BM-:C. Fluorescent array images were collected for both Cy3 and Cy5 with Molecular Dynamics III scanner supported with ImageQuant v5.0. Image intensity data were extracted and analyzed with ArrayVision v8.0 analysis software. Background-corrected data was LOWESS normalized and log ratios were calculated using Avadis v4. Further, mean log ratios were calculated for duplicate spots. Duplicate experiments were carried out for all the dosages.

2014-12-23 | E-GEOD-19157 | biostudies-arrayexpress

A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics

Project description:The rapid repurposing of antivirals is particularly pressing during pandemics. However, rapid assays for assessing candidate drugs typically involve in vitro screens and cell lines that do not recapitulate human physiology at the tissue and organ levels. Here, we show that a microfluidic bronchial-airway-on-a-chip lined by highly differentiated human bronchial-airway epithelium and pulmonary endothelium can model viral infection, strain-dependent virulence, cytokine production, and the recruitment of circulating immune cells. In chips infected with pseudotyped SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), clinically relevant doses of the antimalarial drug amodiaquine inhibited infection, but clinical doses of hydroxychloroquine and other antiviral drugs that inhibit the entry of pseudotyped SARS-CoV-2 in cell lines under static conditions did not. We also show that amodiaquine showed substantial prophylactic and therapeutic activities in hamsters challenged with native SARS-CoV-2. The human airway-on-a-chip may accelerate the identification of therapeutics and prophylactics with repurposing potential.

2021-04-09 | GSE171711 | GEO

RNA-seq of human cell line U2OS treated with chloroquine, amodiaquine and BMH-21

Project description:Ribosome biogenesis has emerged as a potential target for cancer therapy. We have characterize a new biological activity of the antimalarial drug amodiaquine as a inhibitor of ribosome biogenesis. Interestingly, amodiaquine retains the autophagy inhibitory activity of its analog chloroquine, but in addition, displays properties of the ribosome biogenesis inhibitor BMH-21. We performed a RNAseq analysis to identify shared and unique mechanisms of action among these drugs. Gene expression was profiled in U2OS cell line, using 24 samples divided in 4 treatment groups: Untreated, Amodiaquine, Chloroquine and BMH-21, incubated with compounds for 12 hours.

2019-09-01 | E-MTAB-7616 | biostudies-arrayexpress

To investigate the effects of NRF2 inhibitors (pyrimethamine) on mRNA expression in mouse esophageal epithelium.

Project description:To study the effects of NRF2 inhibitors (pyrimethamine) on mRNA expression in mouse esophageal epithelium.

2023-10-12 | GSE235584 | GEO

To investigate the effects of NRF2 inhibitors (pyrimethamine and mitoxantrone) on gene expression in a human esophageal squamous cell carcinoma cell line (KYSE70)

Project description:To study the effects of NRF2 inhibitors (pyrimethamine or mitoxantrone) on human esophageal squamous cell carcinoma cells.

2024-04-22 | GSE173164 | GEO

To investigate the effects of NRF2 inhibitors (pyrimethamine and mitoxantrone) on mRNA expression in a human esophageal squamous cell carcinoma cell line (KYSE70 cells)

Project description:To study the effects of NRF2 inhibitors (pyrimethamine or mitoxantrone) on human esophageal squamous cell carcinoma cells.

2023-10-12 | GSE235587 | GEO

Mus musculus

Project description:Microarray analysis of murine kidney treated with Amodiaquine and Sulfodoxine-Pyrimethamine

| PRJNA120713 | ENA

Mus musculus

Project description:Differential gene expression analysis of Mice liver treated with Amodiaquine and Sulfodoxine-Pyrimethamine

| PRJNA118831 | ENA

Gene Expression during Panobinostat Dosing

Project description:A clinical study evaluating the dosing of an oral HDACi panobinostat in patient infected with HIV-1. Dosing was 20 mg orally, 3 times weekly, every other week for a total of 8 weeks. Gene expression was evaluated in whole PBMCs at baseline (Visit 2), after 3 doses (Visit 4), 4 weeks after dosing (Visit 12) and 6 months after dosing (Visit 13) using the Affymetrix HTA 2.0 gene expression chip

2018-01-30 | GSE109792 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data